Small cell lung cancer: circulating tumor cell lines and expression of mediators of angiogenesis and coagulation
Open Access
- 28 April 2023
- journal article
- research article
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 4 (2) , 355-365
Abstract
Aim: Coagulation is frequently activated in cancer patients and has been correlated with an unfavorable prognosis. To evaluate whether a putative release of tissue factor (TF) by circulating tumor cells (CTCs) represents a target to impair the dissemination of small cell lung cancer (SCLC), the expression of relevant proteins in a panel of permanent SCLC and SCLC CTC cell lines that have been established at the Medical University of Vienna. Methods: Five CTC and SCLC lines were analyzed using a TF enzyme-linked immunosorbent assay (ELISA) tests, RNA sequencing, and western blot arrays covering 55 angiogenic mediators. Furthermore, the influence of topotecan and epirubicin as well as hypoxia-like conditions on the expression of these mediators was investigated. Results: The results demonstrate that the SCLC CTC cell lines express no significant amounts of active TF but thrombospondin-1 (TSP-1), urokinase-type plasminogen activator receptor (uPAR), vascular endothelial-derived growth factor (VEGF) and angiopoietin-2 in two cases. The major difference between the SCLC and SCLC CTC cell lines found was the loss of the expression of angiogenin in the blood-derived CTC lines. Topotecan and epirubicin decreased the expression of VEGF, whereas hypoxia-like conditions upregulated VEGF. Conclusions: Active TF capable of triggering coagulation seems not to be expressed in SCLC CTC cell lines in significant levels and, thus, CTC-derived TF seems dispensable for dissemination. Nevertheless, all CTC lines form large spheroids, termed tumorospheres, which may become trapped in clots of the microvasculature and extravasate in this supportive microenvironment. The contribution of clotting to the protection and dissemination of CTCs in SCLC may be different from other solid tumors such as breast cancer.Keywords
All Related Versions
This publication has 32 references indexed in Scilit:
- Effects of tumor microenviromental factors on VEGF expressionBiomedical Reports, 2013
- Malignant transformation in melanocytes is associated with increased production of procoagulant microvesiclesThrombosis and Haemostasis, 2011
- Molecular mechanisms of metastasis in breast cancer—clinical applicationsNature Reviews Clinical Oncology, 2010
- Tissue factor in tumour progressionBest Practice & Research Clinical Haematology, 2009
- Tissue Factor Expression in Non-small Cell Lung Cancer: Relationship with Vascular Endothelial Growth Factor Expression, Microvascular Density, and K-ras MutationJournal of Thoracic Oncology, 2008
- Tissue factor expression correlates with disease‐specific survival in patients with node‐negative muscle‐invasive bladder cancerInternational Journal of Cancer, 2008
- Cancer and thrombosis: from molecular mechanisms to clinical presentationsJournal of Thrombosis and Haemostasis, 2007
- Prognostic Significance of Tissue Factor in Pancreatic Ductal AdenocarcinomaClinical Cancer Research, 2005
- Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabineCancer, 2005
- Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lungCancer, 1990